LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer
2021 · Cell Death Discovery · 34 citations
https://doi.org/10.1038/s41420-021-00603-z
B
Behnam Ebrahimi
The University of Texas Health Science Center at San Antonio(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
71
Papers
1.1K
Citations
17
h-index
18
i10-index
Behnam Ebrahimi is an academic researcher from The University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Estrogen and related hormone effects & Pluripotent Stem Cells Research & CRISPR and Genetic Engineering. The author has an h-index of 17, co-authored 61 publications.
ORCID: 0000-0003-4588-7525Papers by this author
worksSETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance
2022 · Breast Cancer Research · 29 citations
https://doi.org/10.1186/s13058-022-01520-4
Cardiac progenitor reprogramming for heart regeneration
2018 · Cell Regeneration · 9 citations
https://doi.org/10.1016/j.cr.2018.01.001
Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34
2023 · Breast Cancer Research and Treatment · 6 citations
https://doi.org/10.1007/s10549-023-06958-4
Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer
2026 · Oncogene · 0 citations
https://doi.org/10.1038/s41388-026-03689-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat